ATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (Nasdaq: INHX) today announced it has established a new scientific advisory board to provide the Company with scientific and clinical guidance on its ongoing research and development activities. The Company’s scientific advisory board is composed of distinguished scientists and thought leaders with recognized expertise in virology and infectious diseases. Chairing the Company’s scientific advisory board will be Erik De Clercq, MD, PhD, Professor Emeritus (active retired) at the Katholieke Universiteit Leuven, Belgium and President of the Rega Foundation (Rega Institut V.Z.W.). Dr. De Clercq has invented or co-invented a number of approved antivirals including tenofovir, one of the most widely-used drugs for the treatment of HIV AIDS.
